Of note, a CC AM cell subset with properties of tumor-initiating cells controlled by EZH2 is confirmed to be responsible for tumor recurrence, suggesting that targeting CC AM cells and EZH2 are promising approaches for AM treatment. Here, EZH2 is linked to neoplasm.